Innovation Paying Off For Hutchison MediTech As It Rakes In 327% Revenue Increase
This article was originally published in PharmAsia News
Developing new drugs in China for China has never been better for Hutchinson Chi-Med, reporting annual revenues growing by three-fold. The company sees a breakout year in 2014, driven by promising c-Met inhibitor vilotinib licensed to AstraZeneca.
You may also be interested in...
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.